← Back to Search

Experimental Arm for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by Nasser Hanna, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from start of treatment until death or distant metastasis (estimate 18 months) up to a maximum of 47 months.
Awards & highlights

Study Summary

This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA or IIIB NSCLC. No randomization or blinding is involved.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from start of treatment until death or distant metastasis (estimate 18 months) up to a maximum of 47 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from start of treatment until death or distant metastasis (estimate 18 months) up to a maximum of 47 months. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to Death or Distant Metastasis
Secondary outcome measures
Number of Participants Experiencing Grade 3-4 AE With Adverse Events as a Measure of Safety and Tolerability
Overall Survival
Progression Free Survival

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental ArmExperimental Treatment1 Intervention
Pembrolizumab -200 mg IV 3 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Nasser Hanna, M.D.Lead Sponsor
7 Previous Clinical Trials
368 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,881 Previous Clinical Trials
5,053,596 Total Patients Enrolled
Hoosier Cancer Research NetworkOTHER
68 Previous Clinical Trials
3,662 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Nasser Hanna, M.D. 2015. "Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02343952.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top